This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://localhost/temp/predkladatel/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n10http://bibframe.org/vocab/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11140%2F14%3A10271883%21RIV15-MSM-11140___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11140%2F14%3A10271883%21RIV15-MSM-11140___
rdf:type
n14:Vysledek skos:Concept
rdfs:seeAlso
http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1578&id=17234
dcterms:description
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.
dcterms:title
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report
skos:prefLabel
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report
skos:notation
RIV/00216208:11140/14:10271883!RIV15-MSM-11140___
n3:aktivita
n18:P n18:I
n3:aktivity
I, P(NR9087)
n3:cisloPeriodika
3
n3:dodaniDat
n12:2015
n3:domaciTvurceVysledku
n6:7080123 n6:1821407 n6:4249844 n6:9221670
n3:druhVysledku
n19:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
42561
n3:idVysledku
RIV/00216208:11140/14:10271883
n3:jazykVysledku
n5:eng
n3:klicovaSlova
EGFR mutation; non-small cell lung cancer; erlotinib
n3:klicoveSlovo
n11:EGFR%20mutation n11:non-small%20cell%20lung%20cancer n11:erlotinib
n3:kodStatuVydavatele
IT - Italská republika
n3:kontrolniKodProRIV
[23B4789AF14D]
n3:nazevZdroje
Tumori
n3:obor
n20:FD
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
6
n3:projekt
n9:NR9087
n3:rokUplatneniVysledku
n12:2014
n3:svazekPeriodika
100
n3:tvurceVysledku
Benešová, Lucie Minárik, Marek Pešek, Miloš Krákorová, Gabriela Fínek, Jindřich Fiala, Ondřej
s:issn
0300-8916
s:numberOfPages
4
n10:doi
10.1700/1578.17234
n7:organizacniJednotka
11140